Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
Chemoradiotherapy
Intensity-modulated radiation therapy
Intermediate risk
Nasopharyngeal carcinoma
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
16 Mar 2020
16 Mar 2020
Historique:
received:
05
11
2019
accepted:
02
03
2020
entrez:
18
3
2020
pubmed:
18
3
2020
medline:
3
2
2021
Statut:
epublish
Résumé
This study directs to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone versus IMRT plus chemotherapy in intermediate-risk NPC (stage II and T A total of 124 patients with stage II and T Survival outcomes for patients with stage II and T For intermediate-risk (stage II and T
Sections du résumé
BACKGROUND
BACKGROUND
This study directs to evaluate the efficacy and safety of intensity-modulated radiotherapy (IMRT) alone versus IMRT plus chemotherapy in intermediate-risk NPC (stage II and T
METHODS
METHODS
A total of 124 patients with stage II and T
RESULTS
RESULTS
Survival outcomes for patients with stage II and T
CONCLUSION
CONCLUSIONS
For intermediate-risk (stage II and T
Identifiants
pubmed: 32178698
doi: 10.1186/s13014-020-01508-4
pii: 10.1186/s13014-020-01508-4
pmc: PMC7074987
doi:
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
66Subventions
Organisme : National Natural Science Foundation of China
ID : 81560443
Organisme : Scientific Research and Technology Development Program of Guangxi
ID : 20170109-22
Organisme : Natural Science Foundation of Guangxi Province
ID : 2018GXNSFAA138100
Références
BMC Cancer. 2012 Feb 15;12:68
pubmed: 22336097
J Cancer. 2017 Jan 15;8(2):287-297
pubmed: 28243333
Oral Oncol. 2018 Jan;76:61-67
pubmed: 29290287
J Natl Cancer Inst. 2005 Apr 6;97(7):536-9
pubmed: 15812080
Radiother Oncol. 2012 Sep;104(3):331-7
pubmed: 22103978
Theranostics. 2017 Oct 17;7(19):4825-4835
pubmed: 29187906
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
Eur J Cancer. 2015 Nov;51(17):2587-95
pubmed: 26318726
Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):57-62
pubmed: 15936155
J Clin Oncol. 2015 Oct 10;33(29):3356-64
pubmed: 26351355
J Natl Cancer Inst. 2011 Dec 7;103(23):1761-70
pubmed: 22056739
Onco Targets Ther. 2017 Aug 01;10:3853-3860
pubmed: 28814884
Jpn J Clin Oncol. 2016 Mar;46(3):241-7
pubmed: 26755831
Int J Radiat Oncol Biol Phys. 2011 Jul 1;80(3):661-8
pubmed: 20643517
Lancet. 2005 Jun 11-17;365(9476):2041-54
pubmed: 15950718
Br J Cancer. 2015 Apr 28;112(9):1554-61
pubmed: 25742485
Rep Pract Oncol Radiother. 2012 Mar 06;17(2):71-8
pubmed: 24377003